Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis ... let alone next year, Corporate Social Responsibility is at the heart of Sanofi’s development strategy ...

Sanofi is racing to raise the flag on meningitis awareness—literally. The Paris-based pharma is fittingly symbolizing the “race against time” that is the fight against rapidly progressing ...

Sanofi India Limited, was initially incorporated as Aventis Pharma Limited in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012.

Hawaii had alleged the companies violated state consumer protection laws by marketing Plavix without disclosing that the drug could have a diminished or no effect for some people, particularly of ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to ...

Sanofi has launched Dupixent for COPD in eight countries, said Hudson, who added that 2025 will be the "inflection year," for the treatment in the indication. Related ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with little-known U.S. artificial intelligence research biotech Earendil Labs in a ...

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce ... a standout on a tumultuous day of corporate earnings on Thursday, beating ...

Metabolex has entered into an agreement with Sanofi–Aventis for the development of small molecules that target G protein-coupled receptor 119 (GPR119), the most advanced of which is in a Phase ...

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody amlitelimab didn’t reach the primary endpoint for the highest dose level but ...

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks Consensus Estimate of 90 cents per share. Earnings of €1.79 per share ...

Sanofi plans a phase 3 amlitelimab trial; safety remained consistent over 60 weeks of treatment. Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street ...